ATX 0.00% 6.1¢ amplia therapeutics limited

Ann: Pause in Trading, page-5

  1. 2,131 Posts.
    lightbulb Created with Sketch. 668
    9th October 2023


    AACR OVARIAN CANCER CONFERENCE PRESENTATION

    • Data from preclinical studies in ovarian cancer presented at premier international conference in
    Boston, USA.

    • Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer

    • Data from these studies support clinical study of narmafotinib in ovarian cancer – with plans now commencing with leading international cancer specialists


    I’m guessing it is something to do with this conference ...


    .
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
(20min delay)
Last
6.1¢
Change
0.000(0.00%)
Mkt cap ! $16.67M
Open High Low Value Volume
6.4¢ 6.4¢ 6.1¢ $9.419K 149.7K

Buyers (Bids)

No. Vol. Price($)
3 39253 6.0¢
 

Sellers (Offers)

Price($) Vol. No.
6.1¢ 12705 1
View Market Depth
Last trade - 15.59pm 22/07/2024 (20 minute delay) ?
ATX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.